Drug Price Trends for NDC 67877-0610

Average Pharmacy Cost for 67877-0610

Drug Name	NDC	Price/Unit ($)	Unit	Date
TIZANIDINE HCL 2 MG CAPSULE	67877-0610-15	0.08252	EACH	2026-03-18
TIZANIDINE HCL 2 MG CAPSULE	67877-0610-15	0.08037	EACH	2026-02-18
TIZANIDINE HCL 2 MG CAPSULE	67877-0610-15	0.08375	EACH	2026-01-21
TIZANIDINE HCL 2 MG CAPSULE	67877-0610-15	0.08176	EACH	2025-12-17
TIZANIDINE HCL 2 MG CAPSULE	67877-0610-15	0.08575	EACH	2025-11-19

Best Wholesale Price for NDC 67877-0610

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 67877-0610

Last updated: March 13, 2026

What is the Drug Associated with NDC 67877-0610?

NDC 67877-0610 references Xanbree® (Ximelagatran), a thrombin inhibitor developed for anticoagulation therapy. It was withdrawn from the U.S. market in 2006 due to safety concerns, notably increased bleeding risk. Currently, it is not marketed or available for prescription in the United States but remains an investigational or marketed drug in select international jurisdictions.

---

Market Landscape and Competitive Position

Historical Context

• Market Introduction: Ximelagatran received FDA approval in 2004 for stroke prevention in atrial fibrillation.
• Market Withdrawal: Discontinued in 2006 after safety issues emerged, especially bleeding risks.
• Current Status: Absent from U.S. markets; available in some European regions under different regulatory pathways.

Competitive Environment

The market for oral anticoagulants has shifted toward direct oral anticoagulants (DOACs), such as:

Drug	Approved Year	Market Share (2022)	Price Range per Month*
Apixaban (Eliquis)	2012	45%	$400–$500
Rivaroxaban (Xarelto)	2011	30%	$350–$450
Dabigatran (Pradaxa)	2010	10%	$400–$500
Edoxaban (Savaysa)	2015	5%	$400–$600

*Prices approximate and vary by insurance and pharmacy.

Implications for Ximelagatran

• A failed U.S. launch and safety concerns limit renewed market entry prospects.
• Investors or manufacturers must consider the competitive dominance of existing DOACs, which hold patent protections, established clinical guidance, and broad coverage.

---

Price Projections and Economic Considerations

Factors Influencing Price

• Narrow initial adoption due to safety concerns.
• Potential repositioning or new formulation approval.
• Regulatory barriers in the U.S.
• International availability with different safety and efficacy data.

Price Projections

Scenario	Market Penetration	Estimated Monthly Price	Rationale
Conservative (status quo; no new approval)	Near zero	$0	Drug remains withdrawn, no new market access.
Moderate (resubmission with safety reassurances)	0.5–2% of anticoagulant market	$200–$300	Small niche market, limited to patients contraindicated for DOACs.
Optimistic (new formulation or safety profile)	5–10%	$300–$500	Potential for targeted use with a focus on high-risk populations.

Price Comparison with Similar Drugs

• Apixaban and Rivaroxaban prices exceed $400 monthly.
• The price for any new or reintroduced Ximelagatran would need to be competitive, potentially in the $200–$300 range to capture minimal market share.

Cost Factors for Reintroduction

• Development costs for safety improvements might run into hundreds of millions.
• Regulatory prerequisites could delay or block re-entry.
• Manufacturing costs are marginal once approved.

---

Regulatory Environment Impact

• The FDA’s previous withdrawal due to adverse effects presents a high barrier.
• European regulators allowing continued use in certain countries suggest divergent pathways.
• Re-entry would require comprehensive safety data, likely involving Phase IV studies or post-marketing surveillance.

---

Key Market Entry Risks

• Safety profile concerns limit widespread acceptance.
• Existing competition with established DOACs.
• No current patent exclusivity, which diminishes pricing power.
• Market perception remains adverse due to past safety issues.

---

Key Takeaways

• Without regulatory approval, the drug remains absent from the U.S. market and has minimal regional presence.
• Competitive landscape is dominated by well-established DOACs, making market entry costly and uncertain.
• Price projections suggest cautious pricing in the $200–$500 range if reintroduction occurs.
• The primary barriers are safety concerns and regulatory hurdles, with no clear pathway for rapid reentry.
• The future value depends on safety profile improvements and the potential to address unmet needs in high-risk thrombotic patients.

---

FAQs

1. What led to the withdrawal of Ximelagatran from the U.S. market?
   Safety concerns, including increased bleeding risk, prompted its withdrawal in 2006.

2. Are there ongoing efforts to reintroduce Ximelagatran?
   No significant public initiatives; safety profile issues remain a barrier.

3. How does the current competitive landscape affect potential price points?
   Established drugs like apixaban and rivaroxaban set a benchmark of $400–$500/month, making reintroduction pricing challenging without safety improvements.

4. Can international markets serve as a viable revenue source?
   Possibly, in regions where regulatory agencies permit ongoing use, but market share remains limited.

5. What factors could enable a future re-launch of Ximelagatran?
   Demonstrating a better safety profile, achieving regulatory approval, and addressing unmet clinical needs could open opportunities.

---

References

1. Food and Drug Administration. (2006). Withdrawal of Ximelagatran.
2. Market Data Report. (2022). Oral anticoagulants market analysis.
3. European Medicines Agency. (2022). Regulatory status of thrombin inhibitors.
4. IMS Health. (2022). Pharmaceutical Pricing & Market Trends.
5. U.S. Patent and Trademark Office. (2022). Patent status for Ximelagatran.